Linical Co., Ltd.

Tokyo Stock Exchange 2183.T

Linical Co., Ltd. Revenue for the year ending March 31, 2024: USD 81.32 M

Linical Co., Ltd. Revenue is USD 81.32 M for the year ending March 31, 2024, a -13.69% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Linical Co., Ltd. Revenue for the year ending March 31, 2023 was USD 94.22 M, a -0.75% change year over year.
Linical Co., Ltd. Revenue for the year ending March 31, 2022 was USD 94.93 M, a 2.27% change year over year.
Linical Co., Ltd. Revenue for the year ending March 31, 2021 was USD 92.82 M, a -8.72% change year over year.
Linical Co., Ltd. Revenue for the year ending March 31, 2020 was USD 101.69 M, a -0.34% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Tokyo Stock Exchange: 2183.T

Linical Co., Ltd.

CEO	Mr. Kazuhiro Hatano
IPO Date	Oct. 27, 2008
Location	Japan
Headquarters	Shin-Osaka Brick Building
Employees	662
Sector	Health Care
Industries Pharmaceuticals Research & Consulting

Description

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.

Key trends

Past 5 years